Orphan Drug Designation Granted by the U.S. FDA for Ceflatonin(R)
20 3월 2006 - 1:40PM
PR Newswire (US)
MELBOURNE, Australia and MENLO PARK, Calif., March 19 /PRNewswire-
FirstCall/ -- ChemGenex Pharmaceuticals Limited
(NASDAQ:CXSP)(ASX:CXS) announced today that the United States Food
and Drug Administration (FDA) has granted Orphan Drug status for
the company's most advanced drug, Ceflatonin, for the treatment of
chronic myeloid leukemia (CML). Ceflatonin is the first of a new
class of novel drugs that induces apoptosis (programmed cell death)
and inhibits angiogenesis (new blood vessel formation). Ongoing or
soon to be initiated clinical trials are and will be evaluating
Ceflatonin in a broad range of conditions, including: chronic
myeloid leukemia (CML), myelodysplastic syndromes (MDS) and acute
myeloid leukemia (AML). Orphan drug status is granted by the FDA to
promote the development of drugs for diseases affecting less than
200,000 people in the United States. Orphan drug status entitles
ChemGenex to seven years of market exclusivity for the use of
Ceflatonin in the treatment of CML; protocol assistance by the FDA
to optimize drug development in the preparation of a dossier that
will meet regulatory requirements; and reduced fees associated with
applying for market approval. A similar designation for Ceflatonin
in the European market, with similar advantages, was granted by the
European Union on September 9, 2004, based on a positive
recommendation by the Committee for Orphan Medicinal Products
(COMP) of the European Medicines Agency (EMEA). The European Union
granted Ceflatonin orphan status on October 20, 2004 for the
treatment of acute myeloid leukemia (AML). "The decision by the
U.S. FDA to grant Ceflatonin orphan drug status for CML is further
incentive to move Ceflatonin as quickly as possible through the
clinical development and regulatory approval process worldwide,"
said Greg Collier, ChemGenex chief executive officer and managing
director. "We are very encouraged by the growing body of clinical
data on Ceflatonin in resistant CML, MDS and AML, and by the
ongoing support of key opinion leaders in the field. Now with the
granting of Orphan Drug status by the FDA, we are fully committed
to accelerate our development efforts to help address the unmet
medical needs of CML patients worldwide." About Ceflatonin(R)
Ceflatonin (HHT) is a potent inducer of apoptosis (programmed cell
death) in myeloid cells and inhibits angiogenesis (blood vessel
formation). Ceflatonin has confirmed Phase 2 clinical activity in
resistant CML, both as a single agent and in combination with other
approved drugs. ChemGenex is developing Ceflatonin for the
treatment of CML, myelodysplastic syndrome (MDS) and acute myeloid
leukemia (AML). Recent studies have demonstrated that Ceflatonin
has potential in CML patients who are developing resistance to
tyrosine kinase inhibitor (TKI) therapy, including Gleevec(R), and
in-combination with TKI's in early stage CML to increase the
cytogenetic and molecular response rate. A summary of recent
clinical data on Ceflatonin includes the following studies: * In a
nine patient single-agent Phase 1/2 study in accelerated-phase CML
who had become resistant to Gleevec, seven (80%) patients returned
to chronic-phase and 6 (67%) achieved a complete hematologic
response. * In a separate five patient single-agent Phase 2 study
in late chronic-phase CML, five (100%) achieved a complete
hematologic response and two (40%) achieved a cytogenetic response.
Two patients with detectable resistance mutations achieved a
complete hematologic response and their mutations (p-loop) were not
longer detectable after Ceflatonin treatment. * In another recent
10 patient Phase 1/2 study, Ceflatonin was added to Gleevec in
patients who had a partial or complete cytogenetic response, in
order to reduce bcr-abl transcript counts further. Seven (70%)
patients had a significant decrease in bcr-abl counts. Two patients
with partial cytogenetic responses achieved complete cytogenetic
responses. Two patients achieved a complete molecular response, or
not detectable evidence of residual disease. * Pre-clinical studies
on Ceflatonin have shown both additive and synergistic activity
when combined with Gleevec, as measured by a reduction in the
marker (bcr-abl protein expression) that is a hallmark of
resistance in CML. A multinational Phase 2/3 study in CML patients
harboring the T315I point mutation, known to confer complete
resistance to tyrosine kinase (TKI) inhibitors like Gleevec, is
scheduled to begin in Q2, 2006. A second multinational Phase 2/3
study in CML patients resistant to TKI inhibitors is scheduled to
begin soon thereafter. Each study will include centers in the
United States, Germany, France and Italy. Ceflatonin is not
approved by the FDA as a treatment in any indication and is
currently being evaluated in clinical trials for efficacy and
safety for future regulatory applications. Gleevec(R) is a
registered trademark of the Novartis Pharmaceuticals Corporation.
About Chronic Myeloid Leukemia Chronic Myeloid Leukemia (CML) is a
cancer of the blood cells caused by an acquired genetic defect
called the bcr-abl mutation. This defect occurs when genetic
material from two chromosomes (9 and 22) swaps places, creating the
so-called Philadelphia chromosome. The bcr-abl mutation interferes
with normal cell replication processes, leading to an abnormal
proliferation of white blood cells. CML usually occurs in adults
and typically progresses through three phases. Patients generally
are diagnosed in 'chronic phase', progress through an 'accelerated
phase' and then may die if the disease progresses to 'blast phase'.
CML incidence is relatively consistent occurring at about 1 to 2
per 100,000 people and the global CML market for therapeutics is
estimated at in excess of US$2 billion. Patients with chronic phase
CML have been effectively treated in recent years by the drug
Gleevec. However, over time many patients become resistant to the
therapeutic effects of the drug and the disease progresses. About
ChemGenex Pharmaceuticals Limited (http://www.chemgenex.com/)
ChemGenex Pharmaceuticals is a pharmaceutical development company
dedicated to improving the lives of patients by developing
therapeutics in the areas of oncology, diabetes, obesity, and
depression. ChemGenex harnesses the power of genomics for target
discovery and validation, and in clinical trials to develop more
individualized therapeutic outcomes. ChemGenex's lead compound,
Ceflatonin(R), is currently in phase 2/3 clinical trials for
leukemia and Quinamed(R) is in phase 2 clinical trials for
prostate, breast and ovarian cancers. The company has a significant
portfolio of anti-cancer, diabetes, obesity and depression
programs, several of which have been partnered with international
pharmaceutical companies. ChemGenex currently trades on the
Australian Stock Exchange under the symbol "CXS" and on NASDAQ
under the symbol "CXSP". Safe Harbor Statement Certain statements
made herein that use the words "estimate," "project," "intend,"
"expect," "believe," and similar expressions are intended to
identify forward-looking statements within the meaning of the US
Private Securities Litigation Reform Act of 1995. These
forward-looking statements involve known and unknown risks and
uncertainties which could cause the actual results, performance or
achievements of the company to be materially different from those
which may be expressed or implied by such statements, including,
among others, risks or uncertainties associated with the
development of the company's technology, the ability to
successfully market products in the clinical pipeline, the ability
to advance promising therapeutics through clinical trials, the
ability to establish our fully integrated technologies, the ability
to enter into additional collaborations and strategic alliances and
expand current collaborations and obtain milestone payments, the
suitability of internally discovered genes for drug development ,
the ability of the company to meet its financial requirements, the
ability of the company to protect its proprietary technology,
potential limitations on the company's technology, the market for
the company's products, government regulation in Australia and the
United States, changes in tax and other laws, changes in
competition and the loss of key personnel. These statements are
based on our management's current expectations and are subject to a
number of uncertainties that could change the results described in
the forward-looking statements. Investors should be aware that
there are no assurances that results will not differ from those
projected. DATASOURCE: ChemGenex Pharmaceuticals Limited CONTACT:
Dr. Greg Collier, CEO and Managing Director, Australia -
+61-3-5227-2752, or USA - +1-650-474-9800 ext 103, or Dr. Dennis
Brown, President and Director, USA - +1-650-474-9800 ext 108, or
Australia - +61-3-5227-2703, both of ChemGenex Pharmaceuticals
Limited Web Site: http://www.chemgenex.com/
Copyright
Chemgenex (NASDAQ:CXSP)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Chemgenex (NASDAQ:CXSP)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024